Medical tourism in India: what medical value travel is, and who the patient is

Reviewed on 5 October 2026 by Gaurav Phogat. Statistics checked against their original sources on the same date.

Updated 29 October 2026: added medical tourism in India in numbers (official arrivals 2019 to 2025, source countries, e-Medical visa, Heal in India, Regional Medical Hubs) and the main medical tourism cities in India, each with a marketer’s lens, plus two FAQs.

See every medical value travel guide in one place.

Medical value travel, which most people search for as medical tourism in India, means patients who leave their own country for planned treatment in India, with family alongside them. The patient is rarely one person and rarely the decision maker. Demand clusters by country, language and specialty, and the map moves. Enquiries are lost on reply speed, language, channel and price, not on medicine. Name the segment, tag every enquiry, and fix the first reply first.

Quick summary: Medical tourism in India: what medical value travel is, and who the patient is (swipe)

←→Download the carousel (PDF)

At a glance

Medical value travel means patients who leave their own country for planned treatment in India, usually with family alongside. The patient is rarely the sole decision maker, demand clusters by country, language and specialty, and most enquiries are lost on reply speed, language, channel and price clarity rather than on clinical grounds.

Most conversations about international patients inside Indian hospital groups begin in the wrong place. They begin with a country list, an arrivals target and a plan to attend more exhibitions abroad. The patient turns up late, usually as a number someone hopes can be switched on. In my experience that is why so many international programmes stall after their first year.

Medical value travel is the term the sector uses for patients who leave their own country and come to India for planned treatment. It came out of policy and trade language rather than out of marketing, and it is broader than it sounds. It covers the patient who flies in for one procedure and the family that ends up living here for a season. It covers the case arranged by a facilitator, the case referred by a doctor at home, and the case that starts with a relative in a third country typing a question into a phone at midnight.

This article is the foundation of a series about that business: what it is, who the patient really is, who else is in the room when the decision is made, where the demand comes from, and why most of the work sits outside the hospital building. It is written from a growth, digital and brand seat. There is no clinical advice here, and none of it is about how anyone should be treated.

What medical value travel actually means

Medical value travel covers patients who are not resident in India, have a planned reason to travel, choose a country and then a hospital, and arrive with at least one companion. Each part has operational consequences: visas and payment arrangements, advance clinical opinions, cost estimates, and accommodation and support for the family.

The useful definition is narrow. A patient who is not resident in India, who has a planned reason to travel, who chooses a country and then a hospital, and who arrives with at least one person accompanying them. Everything in that sentence has an operational consequence.

Not resident means paperwork: entry permission, identification, a payment route that crosses a currency line, and a clinical record written somewhere else in a format your systems have never seen. Planned means the decision has a long runway, which is the opposite of the local emergency your front office is built for. Chooses a country first means you are not competing with the hospital down the road, and often not with hospitals at all in the early weeks.

It also helps to say what this is not. A visitor who falls ill here and needs urgent care is a different case with different obligations. A member of the diaspora bringing a parent who already lives in India is a different case again. Domestic patients travelling long distances inside India share much of the journey, but they do not carry the border. Each of these gets counted in the same line of a monthly report, and the moment they are mixed, nobody can tell whether the programme is working.

Who the patient actually is

There is no single international patient. The most useful way to segment them is by who pays: families paying for themselves, often raising money from savings and relatives; patients funded by an employer, community body or home-country scheme; and patients paid for by a relative living in another country. Each behaves differently on speed and documentation.

There is no single international patient, and treating them as one is the first error. The most useful way to sort them is by who is paying, because that decides how the case behaves.

Some families pay for themselves. They raise money from savings, from property, from relatives spread across several countries, and every rupee of the estimate matters to them because the estimate is what they have to raise before they can book a flight. Some are funded by an employer, a community body, or a scheme administered at home, in which case a third party approves the case and a file moves at its own pace. Some are paid for by a relative who lives in a completely different country and has never met your coordinator.

Clinically, the pattern is planned and often second-opinion shaped. A diagnosis has usually been made at home, and the family is asking whether it can be treated, where, and what the whole thing involves. Oncology, cardiac sciences, transplant, orthopaedics, neurosciences and fertility carry much of the travel demand in most programmes. Which of those you can genuinely serve is a clinical and capacity question for your medical leadership, not a marketing one.

The last thing to hold on to: the patient rarely travels alone. One, two or three attendants come along, sometimes for weeks. They eat, sleep, pray, do laundry, send money home and talk to everyone back in the source market about how it is going. Designing for the attendant is not hospitality decoration. It is part of the product.

The people in the room when the decision is made

The person enquiring is rarely the person deciding. The decision usually involves a doctor at home whose opinion carries weight, sometimes a facilitator compiling options, often a relative abroad who pays or researches, and the family members who will travel. Hospitals must answer all of them, not just the patient named on the enquiry.

You are almost never speaking to the person who decides. That single fact reorganises the whole funnel.

There is usually a doctor at home who made the diagnosis and whose opinion carries more weight than any website. There may be a facilitator who compiles options and presents them. There is frequently a relative abroad, often the one earning the most, who quietly holds the veto. In sponsored cases there is an officer who has a file to justify. There is the elder in the family whose blessing makes the trip possible, and there is a neighbour who travelled last year and whose story is treated as evidence.

Each of them needs something different from you. The doctor at home needs a clinical summary and, later, a discharge document they can act on. The facilitator needs speed and a clear scope. The relative abroad needs something to read in a language they are fluent in, at a time that suits their time zone. The sponsor needs a document that survives an audit. The neighbour needs the last family to have been treated well.

The series continues with a closer look at the decisions this group works through before a country is chosen, because the order they make them in is not the order most hospital content assumes.

Where the demand comes from, and why the map keeps moving

Demand clusters: neighbouring countries send volume because journeys are short, East and West Africa send cases travelling further for hard-to-access specialties, and the Middle East and Central Asia send self-paying and funded patients. The map shifts quickly with currency availability, new flights, document processing times and capacity built in home countries.

Demand clusters. Neighbouring countries send volume because the journey is short and the family can come and go. East and West Africa send cases that travel much further, often for specialties that are hard to access closer to home. The Middle East and Central Asia send a mix of self-paying and funded patients. Long-haul markets and diaspora referrals send smaller numbers that behave very differently.

What operators underestimate is how quickly the map shifts. Currency availability changes and a market softens within a quarter. A direct flight opens and a second city starts sending enquiries. Processing times for travel documents lengthen and families defer. Capacity gets built at home for a specialty and that stream thins while another grows. One family returns unhappy and a whole district goes quiet.

None of that is visible from a stall at an exhibition or from the memory of your most senior coordinator. It is visible in enquiry data, if the data is tagged at capture, and nowhere else. A programme that reads its markets from one coordinator’s memory will always be a season behind the families it serves.

My own view: a programme that cannot name its top markets by source city, language and specialty is not running a programme. It is receiving whatever arrives.

Medical tourism in India in numbers

The official numbers come from two places: Bureau of Immigration counts of foreign tourist arrivals whose stated purpose was medical, published by the Ministry of Tourism, and the government’s own summaries of the sector. They are the closest thing to a census the sector has, and they tell a clearer story than most conference slides.

For the next step, see Teleconsultation before travel and follow-up after the patient flies home, NRI patients: the parent in India and the child paying from abroad and Patients from Russia and the Caucasus: how they search and where they land.

• Medical travel has not returned to its 2019 level. Arrivals for medical purposes were 6,97,453 in 2019, recovered to 6,59,356 in 2023, eased to 6,44,387 in 2024 and were 5,07,244 in 2025, about 5.5% of all foreign tourist arrivals that year (Ministry of Tourism, February 2026; PIB, May 2026).
• One market dominates. In 2025 Bangladesh sent 3,25,127 medical travellers, about 64% of the total, followed by Iraq (30,989), Uzbekistan (13,699), Somalia (11,506), Turkmenistan (10,231), Oman (9,738) and Kenya (9,357) (PIB, May 2026).
• Some demand is invisible in visa data. Nepali nationals do not need a visa to enter India, so patients from Nepal do not show up in medical visa counts (Newslaundry and IndiaSpend, April 2025).
• The e-Medical visa is widely available. The e-Medical Visa and e-Medical Attendant Visa are open to nationals of 172 countries, and a separate AYUSH visa for treatment under recognised AYUSH systems was introduced on 27 July 2023 (PIB, May 2026). Families should always check current rules on the official e-Visa site.
• Heal in India is the umbrella. The government describes Heal in India as its flagship initiative for medical value travel, and says a revamped Medical Value Travel Portal for planning, booking, payments and post-treatment care is being upgraded (PIB, May 2026).
• New capacity is planned. The Union Budget 2026-27 introduced a scheme to support States in setting up five Regional Medical Hubs, with the private sector, to promote medical and wellness tourism (PIB Research Unit, 24 February 2026).
• Accreditation is broad. NABH had accredited more than 1,299 hospitals as of 2026 (PIB, May 2026).

The marketer’s lens. A sector where one country supplies close to two thirds of arrivals is a concentration risk, and it behaves like one: when visa issuance to Bangladeshi nationals was restricted from August 2024, hospitals and lodges that depended on that stream saw it fall within weeks (Scroll, December 2024). Read the national numbers as context, not as your forecast. Your own enquiry data, tagged by country, city and language, is the only early warning you will get, which is why I keep coming back to measuring international patient demand and to what marketing teams need to know about medical visas.

Main medical tourism cities in India

Foreign patients do not choose “India” in the abstract. They choose a city, and the choice is shaped by flights, language, the communities already living there and the doctors their own doctor knows. Industry executives have said that direct flight connectivity largely decides where patients go (The Business Standard, July 2021). The government’s own list of JCI-accredited hospitals by city, as of 2022, gives Delhi 9, Mumbai 6, Bengaluru 3, Chennai 2, Hyderabad 2 and Kolkata 1 (PIB, May 2026). Accreditation counts are not rankings, and no city list replaces your own data, but the broad pattern looks like this.

Two patterns matter more than any single city. First, patients cluster where people like them already are: a community of students or traders, a regular flight, a coordinator who speaks the language. Second, the map moves. A new direct route can open a market in a season, and a visa restriction can close one in a month. The same is true inside India, where second cities are starting to receive international enquiries that used to go only to the metros.

The marketer’s lens. If you market a hospital in one of these cities, start with the markets that already reach it, not the ones on an exhibition calendar. Build country landing pages for the two or three source markets your enquiry data shows, in their languages, and say plainly how a family gets from their city to yours. The source-market guides cover the detail: Bangladesh, Maldives, Sri Lanka, the Gulf, Iraq and Yemen, Central Asia, East Africa and the Horn of Africa. People searching for medical tourism companies are usually looking for facilitators; facilitator, direct or hybrid explains when a hospital should work with them.

What the patient is actually buying

International patients are mainly buying certainty of process, not a promised outcome, which nobody should imply. They want to know who will reply, what treatment will cost, how long they will stay, where the family will live and who will help them on arrival. Clear, fast answers to those questions win the choice.

Certainty, mostly. Not the certainty of an outcome, which nobody can offer and nobody should imply. The certainty of process.

Put yourself in the position of someone choosing a hospital in a country they have never visited. You cannot walk in. You cannot ask a colleague who has been. You cannot read the register a regulator keeps, and if you could, you would not know how to weigh it. You cannot tell from a photograph whether a building is clean, well run or even real. Almost every signal you would normally use to judge a hospital is unavailable to you.

So the patient substitutes the signals they can observe. How fast did someone reply. Did that reply come from a person with a name. Did they answer the actual question or send a brochure. Did they write in a language the family reads comfortably. Did the price they were given hold when the bill came. Did anyone follow up when the case went quiet.

Those proxies are unfair, in that they measure your coordination rather than your medicine. They are also rational, because they are all the patient has. The money question does more damage than anything else when handled badly, which is why the estimate that survives arrival gets a full article of its own in this series.

The journey is much longer than the funnel you have drawn

The real international patient journey runs from a symptom or diagnosis at home, through a local doctor’s advice, searches in several languages, a shortlist of countries and then hospitals, multiple enquiries, opinions and estimates, visas, travel, treatment, recovery and follow-up at home. Most hospital funnels cover only a fraction of it.

Write out the real sequence and it runs something like this. A symptom or a diagnosis at home. A conversation with a local doctor. A search, often in a language other than English. A shortlist of countries before a shortlist of hospitals. An enquiry sent somewhere, frequently to several places on the same evening. A medical opinion requested. Reports sent as photographs of printed pages. An estimate. A decision by a group of people in more than one country. Travel documents. Money moved across a border. Flights. Arrival. Admission. Treatment. Discharge. The flight home. Follow-up from thousands of kilometres away. And then, if it went well, the next family from the same street.

Most hospital systems cover four or five of those steps. The rest happen in inboxes, in chat threads, on somebody’s personal phone, and in the head of one coordinator who has been doing this for years. When that coordinator takes leave, the pipeline stops. I have seen that pattern often enough to treat it as the default rather than the exception.

Treating the whole sequence as something you design, instrument and own is the argument made in the international patient funnel as a digital product. For this series, the point is simpler: the journey does not begin at your enquiry form and it does not end at discharge.

Why the enquiry dies, and where

International enquiries die at predictable, non-clinical points: no reply within the first hours, replies asking for information already sent, answers in the wrong language or channel, slow clinical opinions, vague cost estimates and silence after the estimate. Fixing response speed, language and estimate clarity recovers more patients than new campaigns do.

Enquiries die at predictable points, and almost none of them are clinical.

They die in the first few hours, because nobody answered, or because the answer was a form asking for information the family had already sent. They die on language, because the reply arrived in English to a household where one member reads English slowly and nobody wants to admit it. They die on channel, because the message went to email when the family lives on a messaging app. They die on money, because a figure was given casually and then changed. They die on paperwork, because nobody explained what the hospital could and could not provide in support of a travel application, or who in the family would need to be named.

On that last point, be careful and be honest. Entry rules, permitted purposes of travel and the documents required change, and they differ by nationality. No article and no marketing page should state them as current fact. The right line for a hospital is that the family must check the current requirements with the relevant authority in their own country, and that your international desk will provide the hospital documentation that is within your power to provide. Anything more confident than that will eventually be wrong.

The single biggest repair available in this business is the first response, which is why what the first reply must contain is the third article in this series.

What this asks of the hospital, not just the marketing team

Medical value travel fails when one function owns it alone. The enquiry, the clinical opinion, the estimate, admission, accommodation, food and prayer spaces sit with different teams. A named owner with authority to convene clinical, billing, front office and support services is needed to make the experience consistent for travelling families.

Medical value travel fails quietly when it is owned by one function. The enquiry belongs to marketing or the contact centre. The opinion belongs to a consultant who is already full. The estimate belongs to billing. Admission belongs to front office. The room, the food, the prayer space and the laundry belong to support services. The refund belongs to finance. Interpretation belongs to whoever happens to speak the language. The discharge document belongs to medical records. Follow-up belongs to nobody at all.

A working programme has one named owner with the standing to convene those functions, a service definition everyone has agreed, and an escalation path that does not depend on friendship. It also needs a desk that can actually hold a conversation in more than one language, which is a staffing and process design problem rather than a hiring afterthought. That is the subject of building an international patient desk that works in more than one language.

It needs one more thing nobody puts on a slide: the willingness to decline. Cases the hospital cannot genuinely support should be turned down early and kindly. A declined case costs you one enquiry. A badly accepted case costs you a market.

Where to start, and what to leave alone for now

Start with the plumbing rather than a campaign, because existing demand is already leaking. Give the segment one owner, capture country, city, language and source for every enquiry, set reply-time targets, standardise estimates and track enquiries through to arrival. Leave new markets and paid campaigns until the current enquiries convert reliably.

If you are standing up or repairing this function, resist the urge to start with a campaign. Start with the plumbing, because the demand you already have is leaking.

1. Name the segment and give it one owner with the authority to convene clinical, billing, front office and support services.
2. Capture country, source city, language and specialty on every international enquiry, at the moment it arrives, in a field nobody can skip.
3. Measure the time to first human reply and the content of that reply, this month, before changing anything else.
4. Agree one estimate format, one set of exclusions and one person who is allowed to issue it.
5. Pick two markets to serve properly rather than eight to serve badly, and write down why you picked them.

Leave the exhibitions, the country pages and the facilitator contracts until those five are in place. They all work better afterwards, and some turn out to be unnecessary.

The rest of this series takes each of these apart. The thread running through all of it is the same: a family is making an expensive, frightening decision about a place they cannot see, using the only evidence you have given them, which is how you behave before they arrive.

International patient segments compared

International patients behave very differently depending on who pays for their care. The table compares self-paying families, sponsored patients and patients paid for by relatives abroad on decision speed, the people involved and what they need most from a hospital, which helps teams design replies, estimates and support for each segment rather than one generic process.

Key statistics, with sources

Official figures show medical value travel to India is substantial and concentrated. More than half a million foreign nationals came for treatment in 2025, neighbouring Bangladesh supplied by far the largest share, and the government expects the market to nearly double by 2030, which raises the cost of losing enquiries to slow, unclear responses.

• 507,244 foreign nationals arrived in India for medical treatment in 2025, out of 9.15 million total foreign tourist arrivals, according to the Government of India. Source: PIB, Medical and Wellness Tourism in India, May 2026.
• Bangladesh was the largest source of medical travellers to India in 2025, with 325,127 arrivals, followed by Iraq with 30,989, according to the Government of India. Source: PIB, Medical and Wellness Tourism in India, May 2026.
• India’s medical tourism market was estimated at USD 8.7 billion in 2025 and is projected to reach USD 16.2 billion by 2030, according to the Government of India. Source: PIB, Medical and Wellness Tourism in India, May 2026.

Further reading from primary sources

• Government of India: e-Visa (including e-Medical and e-Medical Attendant visas): the official source families should check for visa rules.
• IBEF: Healthcare industry in India: sector overview and growth drivers.

Questions people ask